Biotechnology
Berlin Heals Holding AG Successfully Raises Over 7Million CHF Round for Initiating First Studies of New Less Invasive Approaches
ZUG, Switzerland, Feb. 18, 2025 /PRNewswire/ -- Berlin Heals Holding AG, a late stage MedTech start up, has developed a breakthrough method and a product for the therapy of heart failure. The product - an electronic device called C-MIC - has already successfully been tested in patients in a pilot...
2025-02-18 23:20
2536
3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy
REYKJAVIK, Iceland, Feb. 17, 2025 /PRNewswire/ -- 3Z Pharmaceuticals today announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific evidence that positions the mechanisms engaged by amlodipine, an L-type calcium channel blocker (LTCC), as...
2025-02-17 19:25
2068
Vitafoods India 2025: Angel Yeast Brings Innovative Yeast Protein to Dining Table
MUMBAI, India, Feb. 17, 2025 /PRNewswire/ -- Angel Yeast
2025-02-17 12:01
2848
Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, Feb. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...
2025-02-17 08:00
3034
Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region
* XPOVIO® is the first XPO1 inhibitor approved in Taiwan for the treatment of adultpatients with relapsed/refractory multiple myeloma (R/R MM). * After the mainland of China, South Korea, Australia and Singapore, Taiwan market is the fifth APAC market in which XPOVIO® has been approved for pu...
2025-02-13 17:30
3264
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003
SUZHOU, China, Feb. 13, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003. The study aims to compare the e...
2025-02-13 13:18
2475
Study Results Abstracts From Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) At 2025 ASCO Genitourinary Cancers Symposium
CHENGDU, China, Feb. 13, 2025 /PRNewswire/ -- At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2025, to be held inSan Francisco, USA, from Feb. 13-15, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd （"Kelun-Biotech" will present efficacy and safety ...
2025-02-13 11:25
2025
Southern Star Research Applauded by Frost & Sullivan for Delivering Comprehensive Clinical Trial Solutions and Its Competitive Strategies
Southern Star sets itself apart in the CRO market through a unique combination of trust, operational advantages, deep industry expertise, and a strong commitment to local resources. SAN ANTONIO, Feb. 13, 2025 /PRNewswire/ -- Frost & Sullivan recently analyzed the biotechnology contract research ...
2025-02-13 10:30
2122
Sequential and AMILI Secure Prestigious $1.8M UK-Singapore Collaborative R&D Project to Advance Gut-Skin Microbiome Science
LONDON, Feb. 13, 2025 /PRNewswire/ -- Sequential Skin Ltd, a world leader in skin microbiome testing, and AMILI, a leading expert in gut microbiome science, are proud to announce that they have been awarded the prestigious UK-Singapore Collaborative R&D Grant. The$1.8 million project, supported b...
2025-02-13 06:00
2645
Lion TCR's Liocyx-M004 Receives FDA Clearance to Launch Global Multicenter Phase 2 Clinical Trial in HBV-Related Hepatocellular Carcinoma
SINGAPORE, Feb. 12, 2025 /PRNewswire/ -- On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an international multicenter Phase 2 clinical trial. This ...
2025-02-12 09:00
4165
Sustainable Leather Technology Advances With Collaboration Between Meatable and Pelagen
LEIDEN, Netherlands, Feb. 11, 2025 /PRNewswire/ -- Meatable, a leader in cultivated meat technology, has started a collaboration effort withPelagen, a pioneering company focused on developing animal-free leather. This collaboration enables Pelagen to explore the use of the award-winning opti-ox™ ...
2025-02-11 20:04
2521
Infinitus Secures Approval for National-Level Joint Laboratory Project, Ushering in a New Chapter of China-Europe Scientific Research Collaboration
GUANGZHOU, China, Feb. 10, 2025 /PRNewswire/ – In a significant announcement at the recent Infinitus Global Annual Meeting, Infinitus (China) Company Ltd. secured approval for its Sino-British Joint Laboratory on Health and Aging project. This initiative is part of the intergovernmental internati...
2025-02-11 15:27
2745
Bio X Cell Expands Global Reach with New Distribution Center in Beijing, China
LEBANON, N.H., Feb. 11, 2025 /PRNewswire/ -- Bio X Cell, the world's leading provider of functional antibodies for translational research, is strengthening its global distribution network with the opening of a new distribution center in Beijing, China, in March 2025. This expansion marks the lates...
2025-02-11 15:00
2059
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
SHANGHAI, Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along wit...
2025-02-06 19:40
3579
Anti-HER2 Bispecific ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for the Treatment of HER2-positive Breast Cancer
SUZHOU, China, Feb. 6, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (...
2025-02-06 14:05
3557
Medidata Advances New Frontiers for Life Sciences Through Patient-Centric Experiences, AI-Powered Innovations, and New Patient Engaging Alliances
In the era of the generative economy, Medidata is transforming how industries
are empowering patients with new cure and care experiences and lifelong
engagement
SINGAPORE, Feb. 6, 2025 /PRNewswire/ -- Medidata
2025-02-06 13:00
4070
Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
* Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC * Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) for the treatment of ES-SCLC * Serplulimab has now been approved in China, Europe, and sev...
2025-02-05 22:05
3610
AI & Genomics Advances Bring New Hope to Lung Cancer Burden in Asia
SINGAPORE, Feb. 5, 2025 /PRNewswire/ -- Asia is the region most impacted by lung cancer, accounting for 63.1% of newly diagnosed lung cancers and 62.9% of lung cancer deaths worldwide(1). Many countries have applied low-dose CT scans to screen for this deadly cancer to improve early detection an...
2025-02-05 14:00
5347
Aussie sleeptech firm unveils breakthrough test
MELBOURNE, Australia, Feb. 5, 2025 /PRNewswire/ -- Australian medical technology company Optalert has revealed a breakthrough test for sleep issues, expanding access to sleep health technologies for millions of Australians. The simple test is conducted within 10 minutes on a smartphone, making it...
2025-02-05 13:36
2492
NABR Applauds CITES Standing Committee's Decision Not to Enact Trade Suspension on Cambodia's Long-Tailed Macaques
WASHINGTON, Feb. 5, 2025 /PRNewswire/ -- The National Association for Biomedical Research (NABR) commends the CITES Standing Committee's decision not to enact a trade suspension on long-tailed macaques (Macaca fascicularis) from Cambodia. This decision underscores the international community's st...
2025-02-05 06:48
3113
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 285 media titles]
2025-12-10 16:00
Asia Pacific Defies Global Headwinds: Mastercard Economics Institute 2026 Outlook
[Picked up by 277 media titles]
2025-12-10 09:00